Literature DB >> 24603314

Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.

Jiang Zhu1, Ruo-Bing Ning1, Xiao-Yan Lin2, Da-Jun Chai3, Chang-Sheng Xu4, Hong Xie4, Jin-Zhang Zeng5, Jin-Xiu Lin3.   

Abstract

BACKGROUND: Retinoid X receptor (RXR) has been demonstrated to play an important role in cardiac development and has been implicated in cardiovascular diseases. This study aimed to examine the effects of RXRα agonist bexarotene on pathological left ventricular hypertrophy (LVH) in a spontaneously hypertensive rat (SHR) model and the underlying mechanism.
METHODS: WKY rats served as controls. SHRs were randomized into 3 groups at the age of 4 weeks and were treated (once daily for 12 weeks) with either bexarotene (30 or 100mg/kg body weight) or vehicle alone. Echocardiography was performed to determine cardiac structure and function. Neonatal cardiomyocytes were treated with AngII (10(-7) mmol/L) with or without the indicated concentration of RXRα ligand 9-cis-RA. The protein abundances of β-actin, RXRα, LKB1, phospho-LKB1, AMPK, phospho-AMPK, P70S6K, phospho-P70S6K, ACE, and AT1 receptor were measured along with blood pressure, body weight and angiotensin II (Ang II) levels. The effects of LKB1 downregulation by LKB1 small, interfering RNA were examined.
RESULTS: Treatment of SHRs with bexarotene resulted in significant inhibition of LVH without eliminating hypertension. Immunoblot with heart tissue homogenates from SHRs revealed that bexarotene activated the LKB1/AMPK signaling pathway and inhibited p70S6K. However, the increased Ang II levels in SHR serum and heart tissue were not reduced by bexarotene treatment. Treatment of cardiomyocytes with Ang II resulted in significantly reduced LKB1/AMPK activity and increased p70S6K activity. 9-cis-RA antagonized Ang II-induced LKB1/AMPK and p70S6K activation changes in vitro.
CONCLUSIONS: RXR agonists prevent the inhibition of the LKB1/AMPK/p70S6K pathway and regulate protein synthesis to reduce LVH. This antihypertrophic effect of bexarotene is independent of blood pressure. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  blood pressure; hypertension; hypertrophy; liver kinase B1; retinoid X receptor.

Mesh:

Substances:

Year:  2014        PMID: 24603314     DOI: 10.1093/ajh/hpu017

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  9 in total

Review 1.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

2.  lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway.

Authors:  Cansheng Zhu; Min Wang; Xianguan Yu; Xing Shui; Leile Tang; Zefeng Chen; Zhaojun Xiong
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway.

Authors:  Xiahenazi Aiyasiding; Hai-Han Liao; Hong Feng; Nan Zhang; Zheng Lin; Wen Ding; Han Yan; Zi-Ying Zhou; Qi-Zhu Tang
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

4.  Salidroside Ameliorates Cardiomyocyte Hypertrophy by Upregulating Peroxisome Proliferator-Activated Receptor-α.

Authors:  Hui Gao; Kunming Tian; Yichong Meng; Xueping Liu; Yingfu Peng
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

5.  Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure.

Authors:  Dai Suzuki; Akiko Saito-Hakoda; Ryo Ito; Kyoko Shimizu; Rehana Parvin; Hiroki Shimada; Erika Noro; Susumu Suzuki; Ikuma Fujiwara; Hiroyuki Kagechika; William E Rainey; Shigeo Kure; Sadayoshi Ito; Atsushi Yokoyama; Akira Sugawara
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

6.  Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.

Authors:  M M Mariani; T Malm; R Lamb; T R Jay; L Neilson; B Casali; L Medarametla; G E Landreth
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

Review 7.  AMPK: a balancer of the renin-angiotensin system.

Authors:  Jia Liu; Xuan Li; Qingguo Lu; Di Ren; Xiaodong Sun; Thomas Rousselle; Ji Li; Jiyan Leng
Journal:  Biosci Rep       Date:  2019-09-03       Impact factor: 3.840

8.  Weight changes in hypertensive patients with phlegm-dampness syndrome: an integrated proteomics and metabolomics approach.

Authors:  Chi Zhang; Li Li; Shiping Cheng; Debajyoti Chowdhury; Yong Tan; Xinru Liu; Ning Zhao; Xiaojuan He; Miao Jiang; Cheng Lu; Aiping Lyu
Journal:  Chin Med       Date:  2021-07-07       Impact factor: 5.455

9.  Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy.

Authors:  Mikko T Huuskonen; Sanna Loppi; Hiramani Dhungana; Velta Keksa-Goldsteine; Sighild Lemarchant; Paula Korhonen; Sara Wojciechowski; Eveliina Pollari; Piia Valonen; Juho Koponen; Akihiko Takashima; Gary Landreth; Gundars Goldsteins; Tarja Malm; Jari Koistinaho; Katja M Kanninen
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.